Clik here to view.
Lilly launches trial for automated insulin delivery system
Eli Lilly (NYSE:LLY) yesterday dosed the first patient in a trial of its automated insulin delivery system. The system is a hybrid closed-loop platform that includes a connected insulin pump, a dosing...
View ArticleClik here to view.
Novo Nordisk’s once-weekly Type II diabetes injection wins FDA nod
Novo Nordisk‘s (NYSE:NVO) once-weekly semaglutide injection, Ozempic, has won FDA approval as a therapy for adults with Type II diabetes, the insulin-maker reported today. The injection, given in a...
View ArticleClik here to view.
Sunovion wins FDA nod for inhaled COPD therapy
The FDA has approved Sunovion Pharmaceutical‘s Lonhala Magnair system for the long-term treatment of airflow obstruction in people with chronic obstructive pulmonary disease, the company reported...
View ArticleClik here to view.
Neumentum raises $6m for non-opioid pain-killers
Palo Alto, Calif.-based pharma company Neumentum said today that it raised $6 million in a Series A round through the sale of convertible preferred stock. The company plans to use its newly-acquired...
View ArticleClik here to view.
Lumicell aims $29m Series C at pivotal breast cancer trial and expansion into...
With $28.7 million from a recently-closed Series C round, Lumicell reported today that it plans to launch a pivotal trial of its image-guided cancer surgery tech in breast cancer. The Wellesley,...
View ArticleClik here to view.
Acorda resubmits NDA for inhaled Parkinson’s disease therapy
Acorda Therapeutics (NSDQ:ACOR) said today that it resubmitted its new drug application for Inbrija, an inhaled therapy for people with Parkinson’s disease. The Ardsley, N.Y.-based company was dealt a...
View ArticleClik here to view.
Court dismisses class action suits against Novocure
Two class action lawsuits filed against Novocure (NSDQ:NVCR) and some of its directors and executives in January were dismissed after the court established that it lacked personal jurisdiction over any...
View ArticleClik here to view.
Tandem’s finance chief to retire at year’s end | Personnel Moves – Dec. 8, 2017
Tandem Diabetes Care (NSDQ:TNDM) announced today that its EVP and chief financial exec, John Cajigas, will retire at the end of 2017. The company’s SVP of finance, Leigh Vosseller, is slated to take...
View ArticleClik here to view.
Novaliq’s NovaTears, Omega-3 combo approved in Europe for evaporative dry eye...
Privately-held pharma company Novaliq GmbH said this week that its NovaTears+Omega-3 combo therapy for patients with evaporative dry disease was registered in Europe. The treatment uses Novaliq’s...
View ArticleClik here to view.
Novo Nordisk inks outcomes-based contract with pharmacy benefit manager for...
Novo Nordisk (NYSE:NVO) said today that it inked a value-based contract for its Type II diabetes drug, Victoza, with pharmacy benefit manager Prime Therapeutics. The agreement is part of Prime’s...
View ArticleClik here to view.
FDA approves Sanofi’s short-acting insulin lispro injection
The FDA today approved Sanofi‘s (NYSE:SNY) Admelog insulin lispro injection. The product is indicated to help adults and kids with Type I and Type II diabetes control their blood sugar levels. Admelog...
View ArticleClik here to view.
Appeal board to review Sanofi’s Lantus insulin injection patents
The U.S. Patent and Trademark Appeal Board has instituted inter partes review on all claims against two patents owned by Sanofi (NYSE:SNY) for the company’s Lantus insulin glargine injection. Sanofi...
View ArticleClik here to view.
Shire taps Rani Therapeutics’ oral delivery tech for hemophilia therapy
Shire (NSDQ:SHPG) said this week that it is collaborating with Rani Therapeutics to combine the company’s Rani Pill technology for the delivery of factor VIII therapy in patients with hemophilia A....
View ArticleClik here to view.
Companion Medical launches smart insulin pen in U.S.
Companion Medical started selling its smart insulin pen in the U.S. today, according to the San Diego, Calif.-based company. The InPen system, which combines an insulin injector pen and a smartphone...
View ArticleClik here to view.
Teva to slash 14,000 jobs in restructuring effort
Shares in Teva Pharmaceuticals (NYSE:TEVA) climbed 12% this morning after the company announced it plans to cut more than a quarter of its global workforce, suspend its dividend and shut down research...
View ArticleClik here to view.
pSivida touts pilot osteoarthritis trial for Durasert implant
pSivida (NSDQ:PSDV) touted results today from a Phase I safety and efficacy pilot trial of its sustained-release Durasert implant in patients with osteoarthritis of the knee. The company’s Durasert...
View ArticleClik here to view.
Egalet wins tentative FDA nod for intranasal abuse-deterrent pain-killer
Egalet (NSDQ:EGLT) said today that the FDA tentatively approved an expanded label for its Arymo extended-release pain-relief tablets. The new label includes data from a intranasal human abuse potential...
View ArticleClik here to view.
IntelGenx gets green light to launch Ph2 Alzheimer’s study in Canada
IntelGenx (CVE:IGX) said today that Health Canada approved its application to study its montelukast VersaFilm therapy in adults with mild to moderate Alzheimer’s disease. The Phase IIa proof-of-concept...
View ArticleClik here to view.
European committee backs Novo Nordisk’s once-weekly Type II diabetes therapy
A panel of experts from the European Medicines Agency issued a positive recommendation today for Novo Nordisk‘s (NYSE:NVO) once-weekly diabetes drug, Ozempic. The committee’s recommendation will need...
View ArticleClik here to view.
Novocure wins FDA nod for pivotal pancreatic cancer trial
The FDA has given Novocure (NSDQ:NVCR) the green light to bring the company’s Tumor Treating Fields tech into a pivotal Phase III pancreatic cancer trial. The 556-patient study is designed to assess...
View Article